| Entry |
|
|---|
| Name |
Tesaglitazar (JAN/USAN/INN) |
|---|
| Formula |
C20H24O7S
|
|---|
| Exact mass |
408.1243
|
|---|
| Mol weight |
408.47
|
|---|
| Structure |
|
|---|
| Class |
Antidiabetic agent
DG01685 Insulin sensitizer
DG01795 PPAR gamma agonist
DG01732 Non-thiazolidinedione type PPAR agonist
|
|---|
| Efficacy |
Antidiabetic |
|---|
| Comment |
Treatment of type 2 diabetes and insulin resistance syndrome
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antidiabetic agent
DG01685 Insulin sensitizer
DG01795 PPAR gamma agonist
DG01732 Non-thiazolidinedione type PPAR agonist
D01274 Tesaglitazar
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Thyroid hormone like receptors
Peroxisome proliferator-activated receptor (PPAR)
NR1C1 (PPARA)
D01274 Tesaglitazar (JAN/USAN/INN)
NR1C3 (PPARG)
D01274 Tesaglitazar (JAN/USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 28
1 C8x C 13.1613 -17.5017
2 C8y C 13.1613 -16.1016
3 C8x C 14.3514 -15.4015
4 C8x C 15.6115 -16.1016
5 C8y C 15.6115 -17.5017
6 C8x C 14.3514 -18.2018
7 C1b C 16.8017 -18.2018
8 C1b C 17.9918 -17.5717
9 O2a O 19.1819 -18.2718
10 C8y C 20.4420 -17.5717
11 C8x C 20.4420 -16.1716
12 C8x C 21.6321 -15.4715
13 C8y C 22.8223 -16.1716
14 C8x C 22.8223 -17.5717
15 C8x C 21.6321 -18.2718
16 O2a O 11.9712 -15.4015
17 S4a S 10.7111 -16.1016
18 C1a C 9.5209 -15.4015
19 C1b C 24.0824 -15.4715
20 C1c C 25.2725 -16.1716
21 C6a C 26.4626 -15.4715
22 O6a O 26.4626 -14.0714
23 O6a O 27.6527 -16.1716
24 O2a O 25.2725 -17.5717
25 C1b C 26.4626 -18.2718
26 O3c O 11.6912 -17.1517
27 O3c O 9.7310 -17.1517
28 C1a C 27.7227 -17.5717
BOND 29
1 12 13 2
2 13 14 1
3 14 15 2
4 15 10 1
5 1 2 2
6 2 16 1
7 7 8 1
8 16 17 1
9 2 3 1
10 17 18 1
11 8 9 1
12 13 19 1
13 3 4 2
14 19 20 1
15 9 10 1
16 20 21 1
17 4 5 1
18 21 22 2
19 5 6 2
20 21 23 1
21 6 1 1
22 20 24 1 #Up
23 24 25 1
24 5 7 1
25 17 26 2
26 10 11 2
27 17 27 2
28 11 12 1
29 25 28 1
|
|---|
